Servier to Buy Day One Biopharma for USD 2.5B, Adds USFDA-Approved Brain Tumor Drug Ojemda

Servier has offered $21.50 per share in cash, a premium ‌of 68% to ⁠the ⁠stock's last close. Shares of Day One jumped 65% in morning trade.

The deal will give the company access to Day One's Ojemda, the only U.S. Food and Drug Administration-approved monotherapy for pediatric low-grade glioma, the most common form of brain tumor in children.

Servier already sells ​adult glioma drug Voranigo and the deal ⁠strengthens its ‌presence in the space. The company has ​been pushing ​to build its rare cancer portfolio to ⁠meet its target of 10 billion euros ($11.58 billion) in ​annual revenue by 2030.

Ojemda was approved in ​2024 in patients whose tumors progressed after prior treatment. It is now being tested as a first-line therapy, with trial results expected in the second half of 2027.

Wedbush analyst Robert Driscoll called Day One "an attractive take-out candidate", pointing to the ‌successful launch of Ojemda and potential for future sales if the drug is approved in the frontline ​setting around 2028.

The ​drug generated $155.4 ⁠million in sales in 2025, and is projected to bring $225 million to $250 million in 2026. Ojemda competes with Novartis' combination therapy Tafinlar and ​Mekinist, which requires daily dosing compared with Ojemda's once-weekly regimen.

The companies said the deal is expected to close in the second quarter. Servier expects to fund the transaction through existing cash and investments.